BCL2 and cancer: Interestingly, as opposed to our results in BRCA2-deficient cells, a previous study showed that MMC sensitizes cancer cells to the pro-apoptotic effects of TRAIL by downregulating the antiapoptotic proteins BCL2, MCL-1 and BCL-XL while upregulating several pro-apoptotic proteins including BAX and BIM.